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Summary
AIMS OF THE STUDY: To analyse medical end-of-life de-
cision making among the oldest old (80+ years) in Switzer-
land, focusing not only on treatments withheld or with-
drawn but also on those continued until death.
METHODS: This was a retrospective follow-up study of
deaths registered in Switzerland between August 2013
and January 2014 using a standardised questionnaire
completed by the attending physician. All individuals aged
65 years and older who did not die suddenly and com-
pletely unexpectedly, and who had met the responding
physician prior to death were included (n = 2842). We ex-
amined three age groups: 65–79, 80–89, and 90+ years.
Logistic regression analysis was used to identify age-relat-
ed differences, controlled for place of death and sociode-
mographic characteristics.
RESULTS: In 83.8% of the study population at least one
medical end-of-life decision was made, and for 39.4% the
use of a potentially life-sustaining treatment was docu-
mented. Alleviation of pain and other symptoms with a
possible life-shortening effect was performed with 29%
higher odds among the 90+-year-olds (odds ratio [OR]
1.29, 95% confidence interval [CI] 1.01–1.66) than in the
youngest age group. Withholding or withdrawing potential-
ly life-sustaining treatment with or without the explicit in-
tention to hasten death did not differ with age. However,
when the frequency of withholding a potentially life-sus-
taining treatment was compared with the frequency of us-
ing this treatment (either continued until death or with-
drawn later on), the former was more common in old age
(80–89 years), and particularly in very old age (90+ years)
for most of the treatments studied. This applied especial-
ly for ventilator therapy (80–89 years: OR 2.83, 95% CI
1.82–4.41; 90+ years: OR 6.17, 95% CI 2.89–13.17, com-
pared with 65–79 years), artificial nutrition (ORs 2.33, 95%
CI 1.46–3.71 and 4.44, 95% CI 2.28–8.65, respectively),
and antibiotics (ORs 1.53, 95% CI 1.11–2.09 and 1.57,
95% CI 1.05–2.35, respectively). Age had no independent
impact on artificial hydration.
CONCLUSIONS: The use of some potentially life-sustain-
ing treatments decreased with older age and, in relation,
the relative frequency of withholding such treatments in-
creased. There may be various reasons for this finding:
less benefit of a particular treatment in older patients for
instance due to comorbidities, higher burden of treatment,
and finally a tacit consensus of physicians and patients
that death is nearing.
Keywords: end-of-life care, palliative care, alleviation of
pain and other symptoms, non-treatment decisions, with-
holding and withdrawing treatment, continuing treatment,
age
Introduction
As a result of demographic aging in developed countries,
the proportion of deaths of patients aged 80 years or older
has risen sharply in recent decades. In Switzerland, this
proportion has now reached over one half of all deaths in
men and more than two thirds of all deaths in women [1].
The aging of the population as well as medical technologi-
cal developments occur alongside changes in medical care
and decision making at the end of life [2]. There is little
information available on the circumstances and quality of
care in the final phase of older patients’ lives [3–5]. Partic-
ularly for patients aged 90 years or older, there are no spe-
cific investigations into the incidence and characteristics
of medical end-of-life decisions (MELDs). The oldest old
have been reported to have less access to specialist or pal-
liative care, to receive adequate pain and symptom treat-
ment less often, and to be excluded from decision making
more often [6]. For this reason, it is highly relevant to gain
more insight into what medical decisions are made towards
the end of life in these patients and whether age is a deter-
mining factor.
MELDS include the administration of drugs to alleviate
pain and other symptoms even when such treatment may
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hasten the patient’s death (APS), as well as decisions to
forgo potentially life-sustaining treatment, namely with-
holding and/or withdrawing a certain medical therapy.
These decisions account for the vast majority of MELDs
[2, 7, 8]. Withholding treatment means the decision not to
initiate a treatment that is aimed at prolonging life, where-
as withdrawing treatment means to discontinue an ongoing
treatment [9–12]. Both types of decision can hasten death
and thus may create a tension between prolonging life and
providing the best possible quality of life. For this reason,
despite their frequency in end-of-life care, such decisions
are often difficult and stressful for medical health profes-
sionals [9, 13, 14].
Several studies have shown that APS was used less often
in older patients [3, 15, 16], whereas other studies did not
find any age differences [8, 17, 18]. A systematic review
by Rietjens et al. [2] showed that in most of the studies re-
viewed, APS was used less often in the 80+-year-olds, but
the overall effect was not significant. According to several
studies, forgoing potentially life-sustaining treatment oc-
curred more often in older patients (80+) than in younger
ones [2, 8, 9, 16–20]. In older patients, withholding treat-
ment was generally more frequent than withdrawing treat-
ment [21]. Other studies found that age is unrelated to the
frequency of end-of-life decisions in general [15, 22, 23]
and that the incidence of forgoing treatment in particu-
lar did not significantly differ with age [3, 15]. But many
of these studies did not differentiate between withholding
and withdrawing treatment, and none of them considered
the treatments that were continued until death. However,
it is essential to analyse the frequency of treatments with-
drawn in relation to the total number of treatments given,
that is, cases in which a treatment was withdrawn plus cas-
es in which that treatment was continued until death. We
therefore chose a new approach and compared withholding
treatment not only with withdrawing but also with contin-
uing it [24]. For this purpose, we restricted our analyses to
non-sudden, expected deaths since only these cases were
eligible for an MELD.
The first aim of our study was to describe the incidences
of intensified APS and of treatments withheld/withdrawn
among the oldest old patients in Switzerland prior to death
and to analyse whether they differ with age. The second
aim was to study whether age impacts the frequency of
withholding, withdrawing and continuing specific types of
treatment.
Methods
Data collection
Between 1 August 2013 and 31 January 2014, the Swiss
Federal Statistical Office weekly drew a random sample
of death certificates, encompassing 21.3% of deaths of
people aged 1 year or older in the German-speaking part
of Switzerland, 41.1% in the French-speaking part and
62.9% in the Italian-speaking part. Certifying physicians
were sent a total of 8963 questionnaires, of which 3173
(63.5%), 1538 (51.9%) and 617 (61.7%) were returned
from the German-, French-, and Italian-speaking regions,
respectively, up to 11 June 2014. To ensure anonymity of
both patients and physicians, the questionnaires were sent
to the Swiss Academy of Medical Science where they were
anonymised before being made available for research.
Survey
The standardised survey collected information about
MELDs regarding the patient, as well as physician de-
mographic information. Physicians were asked to indicate
when they had first encountered the patient (including pos-
sibly not until after death) and whether death had been sud-
den and completely unexpected. Further questions inquired
after treatment decisions made at the end of life and the
decision-making process. Multiple-choice questions asked
about specific treatments that were continued until death,
or withheld or withdrawn before death. Demographic in-
formation about the patient was collected from the death
certificate. More details are given elsewhere [23].
Sample
We included all people aged 65 years or older at the time
of death who did not die suddenly and completely un-
expectedly as assessed by the responding physician (n =
3678). We excluded those who died from a physician-as-
sisted death or with whom the responding physician did
not have contact before death. Cases without APS where
only “other treatment” or “other medications” were contin-
ued, withdrawn or withheld were also excluded (n = 134).
This led to a final sample of n = 2842.
Analysis
Data were weighted to adjust for region-, age-, and sex-
specific differences in response rates and to ensure the
sample was representative of all deaths in the sample peri-
od. The regions (German-, French-, and Italian-speaking)
were weighted according to their proportion of deaths in
the total Swiss population.
Descriptive statistics (weighted %) were used to assess the
characteristics of the study population and the frequency
of the different MELDs. Multivariable logistic regression
(odds ratios [ORs], 95% confidence intervals [CIs]) was
used to test the association between patient and care char-
acteristics and odds of specific MELDs. All analyses were
adjusted for sex, marital status, cause of death, and place
of death. Deceased persons were classified into three age
groups: 65–79 (reference group), 80–89, and 90+ years
old. Study methods have been described in more detail
elsewhere [25].
Ethics
The study was issued a waiver as being unproblematic by
the Zurich Cantonal Ethics Board (KEK-StV-Nr. 23/13).
Results
Description of the study population
Mean age of the study population was 83.8 years (95%
CI 83.5–84.2; table 1). There were slightly more women
than men (56.4%) with the percentage rising with age:
43.7% in the youngest age group, 56.6% in the intermedi-
ate group and 69.1% in the oldest one. Overall, 37.5% of
all patients were married, with the proportion decreasing
with age (57.8%, 38.7%, and 14.5%, respectively).
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In the youngest age group, the most common cause of
death was neoplasm (47.7%). This proportion decreased
with age (23.6% in the 80–89-year-olds, 12.7% in the 90+-
year-olds). On the other hand, there was an increase in car-
diovascular diseases with age (16.2% in the 65–79-year-
olds vs 26.4% in the 80–89-year-olds and 33.4% in the
90+-year-olds) and a smaller increase of diseases of the
nervous system (13.6 vs 21.6 and 23.7%, respectively).
Respiratory disease was rarer (11.2% of all cases) and did
not substantially vary across age groups. The same was
true for “other or unknown” diagnoses (16.0% of all cas-
es).
The most common places of death were hospital (37.7%)
and nursing home (35.2%), followed by elderly care res-
idence (12.9%), home (9.6%), palliative care unit (4.3%)
and “other” (0.3%). The youngest patients were most like-
ly to die in a hospital (54.1%), whereas patients aged 90
years or older were most likely to die in a nursing home
(50.5%).
Incidence of MELDs
In 83.8% of all individuals in our study population at
least one MELD was made, and the proportion slightly in-
creased with age (81.7 vs 84.6 vs 84.8%; table 1). How-
ever, this increase was not significant in logistic regression
analysis controlling for place of death and sociodemo-
graphic characteristics (OR 1.24, 95% CI 0.96–1.60 for the
80–89-year-olds and OR 1.28, 95% CI 0.94–1.74 for the
90+-year-olds compared with the 65–79-year-olds; table
2). There were no significant differences in the frequency
of at least one MELD between different causes of death,
places of death or regarding sex and marital status.
The use of intensified APS slightly increased with age
(67.2% in the youngest vs 68.9% in the second and 70.3%
in the oldest group; table 1). Logistic regression (table
2) showed that the increase was significant for the oldest
group compared with the youngest one (OR 1.29, 95% CI
1.01–1.66), but not for the second age group (OR 1.16,
95% CI 0.95–1.43).
Patients who died from non-cancer causes were less likely
to receive APS than those who died from cancer, although
the difference was only significant for diseases of the ner-
vous system (OR 0.77, 95% CI 0.60–0.99). The frequency
of APS was similar in all settings, ranging from 66.2 to
69.6% (compared with hospital deaths: OR 0.83, 95% CI
0.66–1.03 for home deaths and OR 0.99, 95% CI
0.80–1.22 for nursing home deaths).
Withholding or withdrawing a potentially life-sustaining
treatment occurred most often in the 80–89-year-olds
(72.3%), followed by the 65–79-year-olds (69.7%), and
the 90+-year-olds (69.1%). However, logistic regression
showed no significant age-related differences (OR 1.12,
95% CI 0.91–1.38 for the 80–89-year-olds and OR 0.97,
95% CI 0.75–1.24 for the 90+-year-olds). Regarding the
different causes of death, 76.0% of all patients with dis-
eases of the nervous system and 74.9% of all patients with
“other or unknown” diagnoses had a decision to withhold
or withdraw treatment, which was significantly more com-
mon than in cancer patients (OR 1.50, 95% CI 1.15–1.95
and OR 1.37, 95% CI 1.04–1.81, respectively). No signif-
icant differences were found for the other causes of death
(OR 1.03, 95% CI 0.82–1.30 for cardiovascular diseases
and OR 0.97, 95% CI 0.73–1.30 for respiratory diseases).
When the different settings were compared, the frequency
of withholding or withdrawing treatment was significantly
Table 1: Characteristics of the study population (n = 2842).
All (65–90+)
n = 2842
65–79
n = 835
80–89
n = 1242
90+
n = 765
n (%) n (%) n (%) n (%)
Age (years), mean (95% CI) 83.8 (83.5–84.2)
Sex Male 1271 (43.6%) 467 (56.3%) 565 (43.4%) 239 (30.9%)
Female 1571 (56.4%) 368 (43.7%) 677 (56.6%) 526 (69.1%)
Marital status Married 1081 (37.5%) 484 (57.8%) 485 (38.7%) 112 (14.5%)
Unmarried* 1761 (62.5%) 351 (42.2%) 757 (61.3%) 653 (85.5%)
Cause of death Neoplasm 819 (27.5%) 404 (47.7%) 311 (23.6%) 104 (12.7%)
Cardiovascular disease 707 (25.4%) 139 (16.2%) 318 (26.4%) 250 (33.4%)
Respiratory disease 333 (11.2%) 91 (11.0%) 147 (11.3%) 95 (11.3%)
Disease of the nervous system 553 (19.9%) 108 (13.6%) 268 (21.6%) 177 (23.7%)
Other or unknown 430 (16.0%) 93 (11.5%) 198 (17.0%) 139 (19.0%)
Place of death Hospital 1102 (37.7%) 467 (54.1%) 468 (37.0%) 167 (22.0%)
Palliative care unit 117 (4.3%) 71 (9.2%) 37 (3.1%) 9 (1.2%)
Nursing home 955 (35.2%) 153 (19.7%) 430 (35.8%) 372 (50.5%)
Elderly care residence 382 (12.9%) 47 (5.4%) 182 (14.3%) 153 (18.5%)
Home 279 (9.6%) 95 (11.4%) 121 (9.5%) 63 (7.7%)
Other 7 (0.3%) 2 (0.3%) 4 (0.3%) 1 (0.2%)
MELDs Any MELD 2350 (83.8%) 678 (81.7%) 1031 (84.6%) 641 (84.8%)
Intensified APS 1941 (68.8%) 560 (67.2%) 850 (68.9%) 531 (70.3%)
Any potentially life-sustaining treatment
withheld/withdrawn
1959 (70.7%) 577 (69.7%) 866 (72.3%) 516 (69.1%)
Any potentially life-sustaining treatment
continued/withdrawn
1195 (39.4%) 449 (52.2%) 498 (37.7%) 248 (28.9%)
Any potentially life-sustaining treatment
continued until death
897 (29.2%) 334 (38.8%) 380 (28.4%) 183 (20.4%)
APS = alleviation of pain and other symptoms; CI = confidence interval; MELD = medical end-of-life decision Unweighted n, weighted % * Includes single, divorced, widowed, and
“other”.
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less likely at home (65.9%) than in hospitals (71.8%; OR
0.75, 95% CI 0.60–0.94), and as likely in nursing homes
(72.4%) as in hospitals (OR 0.98, 95% CI 0.79–1.21).
The decision to apply a potentially life-sustaining treat-
ment that was either withdrawn later or continued until
death was made in 39.4% of all patients, with rates de-
creasing with increasing age (52.2% in the 65–79-year-
olds, 37.7% in the 80–89-year-olds, and 28.9% in the 90+-
year-olds). In 29.2% of all patients such a treatment was
continued until death – a proportion that also decreased
with age (38.8% in the 65-79-year-olds, 28.4% in the
80-89-year-olds, and 20.4% in the 90+-year-olds).
When analysing the frequency of withholding/withdraw-
ing treatment with and without the explicit intention of
hastening death separately, we found no significant age
pattern for either group (not shown in table).
Types of treatment withheld, withdrawn or continued
until death
Figure 1 shows the weighted percentages of withholding,
withdrawing and continuing all nine specific types of treat-
ment for the three age groups separately. All treatments
were attempted most often in the youngest age group.
There was a clear and consistent decrease with age of treat-
ment attempts in artificial hydration and nutrition, antibi-
otics, ventilator therapy, chemotherapy and dialysis. For
surgery, blood products and radiotherapy the proportion in-
creased slightly in the oldest age group compared with the
middle group. But for all these treatments, case numbers in
older patients were low. The proportions of withdrawing an
already attempted treatment were approximately the same
for all age groups across all types of treatment. Withhold-
ing a treatment was clearly more frequent than withdraw-
ing the same treatment for all types of treatment in all age
categories. Furthermore, withholding a therapy was more
common than attempting (withdrawing plus continuing)
the same therapy for all types of treatment in all age groups
except for artificial hydration and antibiotics, which were
given more frequently than withheld in the youngest age
group, and artificial hydration, which was withheld about
as often as given in the second age group. The proportions
of patients for whom a specific treatment was taken into
consideration (sum of continued, withdrawn and withheld)
decreased with age for all types of treatment except for ar-
tificial nutrition and surgery. The decrease with age was
most pronounced in chemotherapy and ventilator therapy.
The four most common types of treatment were artificial
hydration, antibiotics, artificial nutrition and ventilator
therapy. These four treatments were analysed in more de-
tail by comparing the frequency of withholding the dif-
ferent therapies to withdrawing or continuing them (table
3). The greatest increase with age was found for ventilator
therapy. The 80-89-year-olds were nearly three times as
likely to have ventilator therapy withheld rather than with-
drawn or continued than the 65–79-year-olds (OR 2.83,
95% CI 1.82–4.41). The 90+-year-olds were six times as
likely (OR 6.17, 95% CI 2.89–13.17). A clear increase
with age was also found for artificial nutrition (OR 2.33,
95% CI 1.46–3.71 and OR 4.44, 95% CI 2.28–8.65, re-
spectively), as well as for antibiotics (OR 1.53, 95% CI
1.11–2.09 and OR 1.57, 95% CI 1.05–2.35, respectively).
Age had no independent influence on artificial hydration
(OR 1.05, 95% CI 0.71–1.54 for the 80–89-year-olds and
OR 0.95, 95% CI 0.61–1.47 for the 90+-year-olds).
Place of death had a very strong impact on all four types
of treatment and all of them were more often withheld at
home or in nursing homes than in the hospital. This was
especially true for artificial hydration, which was with-
held about 30 times more often at home (OR 29.26, 95%
CI 20.09–42.60) or in nursing homes (OR 32.64, 95% CI
22.25–47.89) than in the hospital.
With respect to cause of death, there was a significant asso-
ciation between the underlying disease and any of the four
types of treatment. A decision to withhold rather than at-
tempt ventilator therapy and artificial nutrition was signif-
icantly less common in patients who died from non-can-
cer causes than those who died from cancer. For antibiotics
and artificial hydration, the proportion was significant-
ly lower only for cardiovascular and respiratory diseases
compared with cancer.
Table 2: Age and other determinants of medical end-of-life decisions*: multi-variable logistic regression (n = 2842).
Any MELD†
n = 2350
Treatments withheld/withdrawn†
n = 1959
APS†
n = 1941
n (%)‡ OR (95% CI) n (%)‡ OR (95% CI) n (%)‡ OR (95% CI)
Age (years) 65–79 678 (81.7%) Ref. 577 (69.7%) Ref. 560 (67.2%) Ref.
80–89 1031 (84.6%) 1.24 (0.96–1.60) 866 (72.3%) 1.12 (0.91–1.38) 850 (68.9%) 1.16 (0.95–1.43)
90+ 641 (84.7%) 1.28 (0.94–1.74) 516 (69.1%) 0.97 (0.75–1.24) 531 (70.3%) 1.29 (1.01–1.66)
Sex Male 1032 (82.6%) Ref. 874 (70.7%) Ref. 858 (68.3%) Ref.
Female 1318 (84.7%) 1.21 (0.96–1.52) 1085 (70.7%) 1.01 (0.84–1.21) 1083 (69.2%) 1.06 (0.88–1.27)
Marital status Unmarried§ 1452 (83.4%) Ref. 1206 (70.1%) Ref. 1201 (68.7%) Ref.
Married 898 (84.4%) 1.27 (0.99–1.63) 753 (71.6%) 1.08 (0.88–1.32) 740 (68.9%) 1.07 (0.88–1.30)
Cause of death Neoplasm 666 (82.3%) Ref. 538 (68.1%) Ref. 586 (71.4%) Ref.
Cardiovascular disease 576 (83.0%) 0.99 (0.75–1.32) 472 (68.1%) 1.03 (0.82–1.30) 474 (68.4%) 0.82 (0.65–1.04)
Respiratory disease 274 (83.6%) 1.05 (0.74–1.49) 221 (67.4%) 0.97 (0.73–1.30) 222 (68.0%) 0.82 (0.61–1.09)
Disease of the nervous system 468 (85.0%) 1.10 (0.80–1.51) 413 (76.0%) 1.50 (1.15–1.95) 370 (67.2%) 0.77 (0.60–0.99)
Other or unknown 366 (86.2%) 1.22 (0.87–1.72) 315 (74.9%) 1.37 (1.04–1.81) 289 (67.4%) 0.77 (0.59–1.01)
Place of death¶ Hospital 1009 (83.8%) Ref. 859 (71.8%) Ref. 839 (69.6%) Ref.
Home 531 (80.8%) 0.78 (0.60–1.02) 424 (65.9%) 0.75 (0.60–0.94) 442 (66.2%) 0.83 (0.66–1.03)
Nursing home 810 (85.8%) 1.10 (0.85–1.43) 676 (72.4%) 0.98 (0.79–1.21) 660 (69.6%) 0.99 (0.80–1.22)
APS = alleviation of pain and other symptoms; CI = confidence interval; MELD = medical end-of-life decisions; OR = odds ratio * Mutually adjusted for all other listed variables †
Patients with treatments withheld/withdrawn and APS combined are included in all three regression models ‡ Unweighted n, weighted % (percentage of MELD) § Includes single,
divorced, widowed and “other” ¶ Home includes elderly care residence and “other”. Hospital includes palliative care unit
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Withholding ventilator therapy instead of attempting it was
significantly more common among women (OR 1.54, 95%
CI 1.01–2.36), whereas no significant sex differences
could be found for the three other types of treatment stud-
ied in more detail. Marital status had no significant impact
on withholding any of the four treatments.
Figure 1: Weighted percentages of cases where treatment was continued, withdrawn, or withheld by age group: 65–79 (n = 835), 80–89 (n =
1242) and 90+ (n = 765) years old.
Table 3: Withholding the four most common types of treatment compared to those for whom treatment was continued or withdrawn*: multi-variable logistic regression.
Artificial hydration
n = 1360
Antibiotics
n = 1184
Artificial nutrition
n = 853
Ventilator therapy
n = 675
n (%)† OR (95% CI) n (%)† OR (95% CI) n (%)† OR (95% CI) n (%)† OR (95% CI)
Age (years) 65–79 141 (35.7%) Ref. 141 (39.4%) Ref. 163 (65.0%) Ref. 135 (56.8%) Ref.
80–89 273 (50.2%) 1.05 (0.71–1.54) 278 (56.2%) 1.53
(1.11–2.09)
203 (83.5%) 2.33 (1.46–3.71) 220 (78.9%) 2.83 (1.82–4.41)
90+ 189 (60.2%) 0.95 (0.61–1.47) 170 (61.1%) 1.57
(1.05–2.35)
204 (92.3%) 4.44 (2.28–8.65) 121 (91.8%) 6.17
(2.89–13.17)
Sex Male 225 (40.0%) Ref. 251 (45.4%) Ref. 279 (73.7%) Ref. 210 (66.0%) Ref.
Female 378 (55.2%) 1.19 (0.86–1.64) 338 (58.6%) 1.32
(0.99–1.77)
391 (86.3%) 1.40 (0.93–2.13) 266 (81.0%) 1.54 (1.01–2.36)
Marital status Unmarried‡ 400 (53.9%) Ref. 380 (54.9%) Ref. 426 (85.8%) Ref. 289 (80.2%) Ref.
Married 293 (40.3%) 1.00 (0.70–1.42) 209 (48.0%) 1.09
(0.79–1.49)
244 (72.9%) 1.00 (0.64–1.56) 187 (65.7%) 0.94 (0.60–1.47)
Cause of death Neoplasm 152 (45.4%) Ref. 146 (52.8%) Ref. 201 (82.7%) Ref. 140 (85.6%) Ref.
Cardiovascular
disease
119 (43.8%) 0.62 (0.41–0.95) 102 (46.9%) 0.51
(0.34–0.76)
125 (78.4%) 0.38 (0.21–0.68) 117 (68.0%) 0.25 (0.14–0.46)
Respiratory dis-
ease
61 (43.5%) 0.52 (0.33–0.85) 87 (39.3%) 0.33
(0.22–0.50)
59 (79.2%) 0.39 (0.19–0.79) 69 (68.7%) 0.29 (0.14–0.58)
Disease of the
nervous system
185 (66.2%) 0.89 (0.55–1.45) 164 (73.2%) 1.15
(0.73–1.81)
200 (85.9%) 0.45 (0.24–0.84) 93 (77.8%) 0.27 (0.14–0.54)
Other or unknown 86 (39.7%) 0.93 (0.57–1.54) 90 (48.2%) 0.65
(0.42–1.00)
85 (70.7%) 0.34 (0.18–0.64) 57 (64.6%) 0.24 (0.12–0.49)
Place of death§ Hospital 92 (13.5%) Ref. 160 (30.4%) Ref. 219 (62.3%) Ref. 217 (59.3%) Ref.
Home 184 (81.4%) 29.26 (20.09–42.60) 148 (70.6%) 5.24
(3.57–7.67)
165 (91.1%) 4.82 (2.73–8.51) 102 (93.0%) 6.36
(3.08–13.15)
Nursing home 327 (83.2%) 32.64 (22.25–47.89) 281 (72.5%) 5.51
(3.99–7.60)
286 (94.8%) 8.98 (4.87–16.58) 157 (92.2%) 5.32 (2.88–9.84)
CI = confidence interval; OR = odds ratio * Mutually adjusted for all other listed variables † Unweighted n, weighted % (percentage of MELD) ‡ Includes single, divorced, widowed
and “other” § Home includes elderly care residence and ‘other’. Hospital includes palliative care unit.
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Discussion
To our knowledge, this is the first nationwide study of
MELDs that specifically includes and focuses on the oldest
old patients while differentiating between withholding,
withdrawing, and continuing treatment until death. Our re-
sults show a number of substantial age differences in the
most common MELDs and confirm that the oldest old pa-
tients are not a homogeneous group, but that there are rele-
vant differences between the ages 80-89 and 90+ years.
Incidence of APS in relation to age
The frequency of APS increased across the three age
groups and varied from 67.2% to 70.3%. The increase
was significant for the oldest old (90+) compared to the
youngest age group (65–79). To the best of our knowledge,
this gradient has never been described. Previous studies
showed a decreasing use of APS with age [3, 15, 16] or
no significant age differences at all [2, 8, 17, 18]. A rea-
son for this discrepancy may be that we compared the 90+
and 80–89-year-old groups with the 65–79-year-old pa-
tients, whereas all other studies compared 80+-year-olds
to <80-year-olds. In addition, almost all previous studies
on APS, with the exception of one [15], assigned to each
death only one MELD, namely the decision with the most
explicit intention of shortening life, whereas we allowed
more than one MELD per case. This may of course con-
tribute to the difference in results. An explanation as to
why elderly people received more intensified APS may be
that they more often prefer treatment options that aim to
provide the best possible quality of life rather than pro-
longing life at all costs [26]. Our study showed that APS
was most frequent in cancer patients, which is in line with
findings of other studies [16, 18].
Incidence of withholding/withdrawing treatment in re-
lation to age
In more than four out of five non-sudden deaths in patients
aged 65 years or older, at least one MELD had been made
prior to death. The incidence of MELDs in total did not
significantly differ with age, which is consistent with pre-
vious research [3, 15, 17, 22]. The frequency of withhold-
ing/withdrawing treatment did not significantly differ with
age, either. Only two previous reports came to the same
conclusion [3, 15]. They chose the same approach as we
did and included only non-sudden, expected deaths in the
denominator. This has been shown to be more valid since
only these deaths were eligible for an MELD [3]. Most pre-
vious studies found an increasing incidence of withhold-
ing/withdrawing treatment with age and most of them in-
cluded all deaths in the denominator [8, 9, 16, 18]. This
approach might skew the data because younger patients
may be more likely to die from sudden, unexpected deaths.
In addition, the prioritisation of MELDs in nearly all pre-
vious studies could be a relevant reason why our study
had different results. All studies that found a significant
age difference used this method, whereas the only study
that permitted more than one MELD per case [15] found
no significant age difference in withholding/withdrawing
treatment, which is consistent with the approach and result
of our study.
In the analysis of decisions with the explicit intention of
hastening death, no significant age differences were found.
Seale et al. [22] reported the same finding and Chambaere
et al. [15] even showed a decrease in withholding or with-
drawing treatment with the intention to hasten death. This
indicates that the elderly, who are often considered a vul-
nerable patient group [2], are not more frequently exposed
to withholding or withdrawing treatment with intentional
life-shortening. Other studies support this finding, showing
that decisions to withhold or withdraw life-prolonging
treatment were most often made because there was no
chance of improvement and the patient was recognised as
being near death, which led to promoting patient comfort
as the main goal of treatment [9, 22, 27].
A reason why there were no significant age differences
in withholding/withdrawing treatment in general may be
that it is a too broad and nonspecific category. The various
types of treatment can have very different characteristics
regarding the circumstances in which they are used, the
potential life-prolonging effect or the burden of treatment
[28]. Therefore, we analysed them separately.
Withholding, withdrawing and continuing different
types of treatment
Although the frequency of withholding/withdrawing treat-
ment did not depend on age, significant age differences
were found when different types of therapies were
analysed separately and when withholding a particular
treatment was compared with applying (withdrawing plus
continuing) the same treatment. Withholding treatment
was generally more common than withdrawing and con-
tinuing it for nearly all types of treatment, especially in
the oldest patients (90+). This is consistent with findings
from other studies [9, 20, 21]. The proportion of patients
for whom a particular treatment was attempted clearly de-
creased with age for nearly all treatments. Increased co-
morbidity and mortality risk in older age can lead to treat-
ments being considered less promising from the start and
therefore being withheld rather than attempted [2, 21]. In
addition, older patients often prefer comfort care rather
than prolonging life at all costs [9]. Moreover, it has been
shown that even after adjustment for patients’ care prefer-
ences and prognosis, severely ill older patients are treated
less aggressively than younger ones [29]. For withholding
artificial hydration compared with attempting it, no signif-
icant age differences could be found. However, place of
death had a strong impact on artificial hydration, which
was about 30 times more likely to be withheld at home or
in nursing homes than in hospital. The benefits and bur-
dens of the use of artificial hydration in end-of-life care are
still controversial [30–32]. There are studies that found no
effect of artificial hydration on symptom control, whereas
others argue that it is still considered the minimum stan-
dard of end-of-life care [24, 33, 34]. Our results suggest
that the latter is particularly the case in hospitals.
High-technology treatments with a high potential of being
burdensome, such as surgery, oncotherapy, dialysis or ra-
diotherapy, were rarely considered (sum of withholding,
withdrawing and continuing) and much more often with-
held than withdrawn or continued. This was particularly
true for the oldest old patients and corresponds to the cur-
rent ethical view that therapies with little benefit compared
with burden should be avoided [35].
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The decision to continue a potentially life-sustaining treat-
ment until death was made less often in older patients,
whereas the proportion of treatments withdrawn compared
with applied was about the same over all three age groups
for all types of treatments. Potentially life-sustaining treat-
ments were less often applied in older patients, which ex-
plains why they were less often continued until death: a
treatment that has never been used cannot be continued.
However, the frequency of withdrawing an already applied
treatment did not decrease with age. The decision to with-
draw an already applied treatment therefore appears to be
not primarily dependent on age, but could also be related
to factors such as the current clinical status and the burden
of symptoms.
Strengths and limitations
The mortality follow-back study method used was rated as
highly reliable [3, 8, 16–18, 36] and even if the optimal
phrasing of the questionnaire is controversial [37, 38], this
kind of study is still considered the gold standard for inves-
tigating end-of-life decision making on a population level
[23]. A strength of the questionnaire is that only descrip-
tive questions were asked and no sensitive terms such as
“passive euthanasia” were used [28], since it is known that
there are still uncertainties among physicians as to what
these terms mean [39–42]. Other methodological strengths
were the high response rates (63.5%, 51.9%, and 61.7% in
the German-, French-, and Italian-speaking region, respec-
tively) and the large and representative region-wide sample
sizes for all deaths in Switzerland in 2013. This allowed us
to analyse all age groups up to the oldest old in different
settings, to disentangle withdrawing, withholding and con-
tinuing treatment, and to examine the individual types of
treatment separately. Compared with previous studies, our
study therefore provides a highly accurate picture of the
end-of-life decisions in the oldest old, providing greater in-
sight into clinical practice.
Nevertheless, some limitations need to be considered. The
case numbers for rarer types of treatment, especially
among the oldest old patients, were too low for reliable
quantitative analyses. Larger studies to assess age differ-
ences in the oldest old in all types of treatments are needed.
Since the data were collected retrospectively, there is al-
ways a risk of memory bias. To minimise this problem,
time between death and completion of the questionnaire
was kept as short as possible and physicians were able
to use the patient’s medical records as a memory aid. Al-
though the response rates were relatively high, there is
still the possibility of nonresponse bias, especially since
MELDs with a life-shortening effect are a sensitive topic.
However, studies that investigated nonresponders showed
that nonresponse did not cause sociodemographic distor-
tion and was most often due to a lack of time and not
because of more relevant reasons such as the physician’s
personal attitude towards end-of-life decisions [22, 23, 43,
44]. Our study is based on self-reports of physicians and
therefore depends on their assessment of the situation;
however, this approach is the most appropriate to examine
their medical end-of-life practices [23]. In addition, we had
no information as to whether a decision to withhold, with-
draw or continue a therapy was appropriate or whether the
decision was in line with patients’ preferences.
And finally, we did not take into account possible regional
variations. A previous analysis revealed that MELDs in to-
tal and decisions to withhold or withdraw treatment in par-
ticular were more common in the German-speaking part
of Switzerland than in the French- and Italian-speaking re-
gions. However, no significant regional differences were
found for different types of treatment, except for artificial
hydration being more likely to be withheld in the German-
than in the French-speaking part of Switzerland [24, 25].
Conclusions
In conclusion, we can state that MELDs were common
among patients above the age of 65 years, and that the fre-
quency of any MELD versus none did not significantly
vary by age. However, the use of APS significantly in-
creased in patients over 90 years old, which is in line with
previous research. The incidence of withholding/with-
drawing treatment did not significantly differ with age.
However, if one considers that potentially life-sustaining
treatments were generally attempted less often in oldest
old (80+ years) than in younger old patients (65–79 years),
the relative frequency of withholding such treatments in-
creased for most of the treatments studied. Since demo-
graphic aging occurs in all developed countries, many of
our results may be generalised to other countries.
Nonetheless, it is important to consider that MELDs in
themselves do not say anything about the quality of end-
of-life care [9]. Our study could not investigate whether
certain MELDs contributed to the best possible quality of
treatment and dying. Further studies are needed to deter-
mine whether MELDs are in line with best care practices,
patient’s wishes and best possible quality of life. In addi-
tion, insight into the physicians’ understanding of the ben-
efits and burdens of different life-prolonging treatments
would be helpful to assess the need for better education
in end-of-life care and promote quality of care. A recent
analysis of the Swiss 2013 MELD study revealed that the
physician’s training in end-of-life care (e.g., country of ed-
ucation or year of graduation) had a significant impact on
the frequency of MELDs and the propensity to discuss
MELDs with patients and relatives [45]. And lastly, clear-
er guidelines would be desirable to help physicians un-
derstand how to deal with the often challenging decision
to withhold, withdraw or continue different treatments in
complex situations [21].
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